Literature DB >> 24530774

High hexacosanoic acid levels are associated with coronary artery disease.

Tetsuro Miyazaki1, Kazunori Shimada2, Makoto Hiki2, Atsumi Kume2, Yohei Kitamura3, Kyoichi Oshida4, Naotake Yanagisawa3, Takashi Kiyanagi2, Rie Matsumori2, Hiroyuki Daida2.   

Abstract

AIMS: Levels of saturated very long chain fatty acids (VLCFAs) are associated with coronary risk factors, including metabolic syndrome (MS), atherogenic lipoproteins, and systemic inflammation. However, the relationship between circulating levels of saturated VLCFA and coronary artery disease (CAD) remains unclear.
METHOD: We enrolled 100 consecutive CAD patients and 40 age-, gender-, and body mass index (BMI)-matched healthy control subjects. The levels of hexacosanoic acid (C26:0), a VLCFA, in whole blood were measured by gas-liquid chromatography mass spectrometry.
RESULTS: C26:0 levels were significantly higher in the CAD group than in the control group (2.42±0.32 vs. 2.27±0.24 μg/ml, P=0.01) and positively correlated with BMI (r=0.23, P=0.008), triglyceride levels (r=0.22, P=0.01), and hypertension (P=0.01). CAD patients with MS showed the highest C26:0 levels adjusted by hematocrit. Furthermore, adjusted C26:0 levels in CAD patients without MS were higher than those in controls (P=0.02), suggesting that C26:0 levels increased with the presence of CAD independent of MS. Our multivariate analysis revealed that high C26:0 levels in whole blood is an independent marker for CAD even after adjustment for age, gender, BMI, lipid profiles, fasting plasma glucose, and blood pressure.
CONCLUSION: High C26:0 levels in whole blood may be an independent marker for identifying the risks of CAD.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Hexacosanoic acid; Metabolic syndrome; Peroxisomal dysfunction; Saturated very long-chain fatty acid

Mesh:

Substances:

Year:  2014        PMID: 24530774     DOI: 10.1016/j.atherosclerosis.2014.01.031

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Circulating Very-Long-Chain Saturated Fatty Acids and Incident Coronary Heart Disease in US Men and Women.

Authors:  Vasanti S Malik; Stephanie E Chiuve; Hannia Campos; Eric B Rimm; Dariush Mozaffarian; Frank B Hu; Qi Sun
Journal:  Circulation       Date:  2015-06-05       Impact factor: 29.690

2.  Significance of Serum Polyunsaturated Fatty Acid Level Imbalance in Patients with Acute Venous Thromboembolism.

Authors:  Masaru Hiki; Tetsuro Miyazaki; Kazunori Shimada; Yurina Sugita; Megumi Shimizu; Tatsuro Aikawa; Shohei Ouchi; Tomoyuki Shiozawa; Kiyoshi Takasu; Shuhei Takahashi; Atsutoshi Takagi; Katsumi Miyauchi; Hiroyuki Daida
Journal:  J Atheroscler Thromb       Date:  2017-03-24       Impact factor: 4.928

3.  An individual participant data meta-analysis on metabolomics profiles for obesity and insulin resistance in European children.

Authors:  Christian Hellmuth; Franca F Kirchberg; Stephanie Brandt; Anja Moß; Viola Walter; Dietrich Rothenbacher; Hermann Brenner; Veit Grote; Dariusz Gruszfeld; Piotr Socha; Ricardo Closa-Monasterolo; Joaquin Escribano; Veronica Luque; Elvira Verduci; Benedetta Mariani; Jean-Paul Langhendries; Pascale Poncelet; Joachim Heinrich; Irina Lehmann; Marie Standl; Olaf Uhl; Berthold Koletzko; Elisabeth Thiering; Martin Wabitsch
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

4.  The Impact of Kidney Transplantation on the Serum Fatty Acid Profile in Patients with End-Stage Kidney Disease.

Authors:  Maciej Śledziński; Aleksandra Hliwa; Justyna Gołębiewska; Adriana Mika
Journal:  Nutrients       Date:  2022-02-12       Impact factor: 5.717

5.  Risk of diabetes associated with fatty acids in the de novo lipogenesis pathway is independent of insulin sensitivity and response: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  Waqas Qureshi; Ingrid D Santaren; Anthony J Hanley; Steven M Watkins; Carlos Lorenzo; Lynne E Wagenknecht
Journal:  BMJ Open Diabetes Res Care       Date:  2019-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.